紫杉醇及蒽环类药物联合化疗对浸润性乳腺癌HER-2状态的影响分析

Impact of combination chemotherapy of paclitaxel and anthracycline drugs on HER-2 status in invasive breast cancer

目的分析紫杉醇及蒽环类药物联合化疗对浸润性乳腺癌人类表皮生长因子受体-2(HER-2)状态的影响。方法选择2013年4月至2014年5月收治的98例浸润性乳腺癌患者,按照入院顺序将患者分为观察组(49例)和对照组(49例)。对照组采取CAF方案进行治疗,观察组患者采取CTX方案+紫杉醇及蒽环类药物。对所有患者的化疗方案和临床病理特征进行记录,主要为腋窝淋巴结状态、激素受体状态以及HER-2表达状态。结果在HER-2阳性的患者当中,观察组患者的无病生存率为95.00%(38/40),对照组患者的无病生存率为65.79%(25/38),两组比较差异有统计学意义(P<0.05);就激素受体阳性的患者而言,观察组患者的无病生存率是91.43%(32/35),明显高于对照组的72.22%(26/36),差异有统计学意义(P<0.05);在腋窝淋巴结阳性的患者中,观察组患者的无病生存率是95.24%(40/42),明显高于对照组的71.79%(28/39),差异有统计学意义(P<0.05)。结论紫杉醇及蒽环类药物联合化疗能够改善浸润性乳腺癌HER-2阳性状态。

Objective To analyze the impact of the combined chemotherapy of paclitaxel and anthracycline drugs on human epidermal growth factor receptor 2（HER-2）status in invasive breast cancer.Methods 98 cases of invasive breast cancer in our hospital from April 2013 to May 2014 were selected and divided into the observation group（49cases）and the control group（49cases）according to the admission order.The control group took the CAF scheme for conducting treatment,while the observation group adopted the CTX scheme plus paclitaxel and anthracyclines drugs.The chemotherapeutic schemes and clinicopathological features were recorded,mainly including axillary lymph node status,hormone receptor status and HER-2expression status.Results In the patients with HER-2-positive,the disease-free survival rate in the observation group was 95.00%（38/40）,which in the control group was65.79%（25/38）,the difference was statistically significant（P〈0.05）;in the hormone receptor-positive patients,the disease-free survival rate in the observation group was 91.43%（32/35）,which was significantly higher than 72.22%（26/36）in the control group,the difference was statistically significant（P〈0.05）;in the axillary lymph node-positive patients,the disease-free survival rate in the observation group was 95.24%（40/42）,which was significantly higher than 71.79%（28/39）in the control group,the difference was statistically significant（P〈0.05）.ConclusionThe combination chemotherapy of paclitaxel and anthracycline drugs can improve the HER-2-positive status in invasive breast cancer.